pipette
ESEspañol
Medicine & healthTreatments & drugs

The nucleoside analog kamuvudine-9 shows protective and therapeutic efficacy in a mouse model of multiple sclerosis

Praveen Yerramothu, Kameshwari Ambati, Joseph Magagnoli, Meenakshi Ambati, Thendral Velmurugan, Dijing Yu, Jing Zhang, Jingjing Zhang, Tammy H. Cummings, Joseph Dan Khoa Nguyen, Claire C. Thomas, Vidya L. Ambati, Kaitlyn Cheng, Maksud Juraev, Roshni Dholkawala, Felipe L. Pereira, Peirong Huang, Ayami Nagasaka, Yosuke Nagasaka, Madhuri Rudraraju, Ashley Ban, Ivana Apicella, 蔡小于, Ranjith Konduri, Rhea Zahir, Elizabeth L. Frost, John R. Lukens, Ruwen Yin, Frederik Brøndsted, Cliff I. Stains, Makoto Ono, Brian P. Delisle, Jamie Horn, Markos L. Leggas, Jeffrey L. Dupree, S. Scott Sutton, Bradley D. Gelfand, Shao-Bin Wang, Jayakrishna Ambati

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
Here, we report that in the experimental autoimmune encephalitis mouse model of MS, treatment with kamuvudine-9 (K-9), an NRTI derivative with an enhanced safety profile, prevented further neurological deficits and reversed preexisting paralysis and vision loss.
Limitation the authors admit
NRTI use was also associated with a reduction in relapse rate in individuals with MS. These findings provide a rationale for further investigating K-9 for treating MS.
Read the paper

Appeared: Friday, September 25. Science Translational Medicine. Peer-reviewed journal.

DOI: 10.1126/scitranslmed.aei2870

All new papers on Treatments & drugs